MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) today presented safety and efficacy data from the company’s extensive Endeavor® drug-eluting stent clinical trial program at a special U.S. Food and Drug Administration advisory panel meeting convened to discuss growing concerns about drug-eluting stent safety. Specifically, the data demonstrates a significant reduction in the need for repeat procedures compared to bare metal stent controls, and a low rate of stent thrombosis in approximately 1,300 patients followed for two to three years in Endeavor clinical trials.
